Is platelet activating factor (PAF) an important mediator in bronchial asthma?
The development of selective PAF receptor antagonists may provide a novel approach to the treatment of human bronchial asthma. In preclinical animal models of human asthma, PAF receptor antagonists have been found to be efficacious in blocking antigen-induced changes in lung function. However, the m...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/S0962935192000541 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551332480811008 |
|---|---|
| author | R. H. Gundel H. O. Heuer L. G. Letts |
| author_facet | R. H. Gundel H. O. Heuer L. G. Letts |
| author_sort | R. H. Gundel |
| collection | DOAJ |
| description | The development of selective PAF receptor antagonists may provide a novel approach to the treatment of human bronchial asthma. In preclinical animal models of human asthma, PAF receptor antagonists have been found to be efficacious in blocking antigen-induced changes in lung function. However, the majority of these models involve acute inflammatory events and transient changes in lung function and, therefore, their relevance to human asthma is questionable. In a recent study with a primate model of chronic airway inflammation and hyperresponsiveness, we have shown that treatment with a PAF receptor antagonist had no effect on reducing chronic inflammation and hyperresponsiveness. Similarly, recent studies in human asthmatics with PAF receptor antagonists have failed to show efficacy in blocking allergen-induced airway responses or to have any steroid sparing effects in patients with ongoing asthma. Thus, it seems that PAF may not be a key mediator which can be blocked and thereby provide therapy for bronchial asthma. |
| format | Article |
| id | doaj-art-be84465fa8a34df5a72a8090df8c7ade |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1992-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-be84465fa8a34df5a72a8090df8c7ade2025-02-03T06:01:45ZengWileyMediators of Inflammation0962-93511466-18611992-01-011636736910.1155/S0962935192000541Is platelet activating factor (PAF) an important mediator in bronchial asthma?R. H. Gundel0H. O. Heuer1L. G. Letts2Department of Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 06877, CT, USADepartment of Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 06877, CT, USADepartment of Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 06877, CT, USAThe development of selective PAF receptor antagonists may provide a novel approach to the treatment of human bronchial asthma. In preclinical animal models of human asthma, PAF receptor antagonists have been found to be efficacious in blocking antigen-induced changes in lung function. However, the majority of these models involve acute inflammatory events and transient changes in lung function and, therefore, their relevance to human asthma is questionable. In a recent study with a primate model of chronic airway inflammation and hyperresponsiveness, we have shown that treatment with a PAF receptor antagonist had no effect on reducing chronic inflammation and hyperresponsiveness. Similarly, recent studies in human asthmatics with PAF receptor antagonists have failed to show efficacy in blocking allergen-induced airway responses or to have any steroid sparing effects in patients with ongoing asthma. Thus, it seems that PAF may not be a key mediator which can be blocked and thereby provide therapy for bronchial asthma.http://dx.doi.org/10.1155/S0962935192000541 |
| spellingShingle | R. H. Gundel H. O. Heuer L. G. Letts Is platelet activating factor (PAF) an important mediator in bronchial asthma? Mediators of Inflammation |
| title | Is platelet activating factor (PAF) an important mediator in bronchial asthma? |
| title_full | Is platelet activating factor (PAF) an important mediator in bronchial asthma? |
| title_fullStr | Is platelet activating factor (PAF) an important mediator in bronchial asthma? |
| title_full_unstemmed | Is platelet activating factor (PAF) an important mediator in bronchial asthma? |
| title_short | Is platelet activating factor (PAF) an important mediator in bronchial asthma? |
| title_sort | is platelet activating factor paf an important mediator in bronchial asthma |
| url | http://dx.doi.org/10.1155/S0962935192000541 |
| work_keys_str_mv | AT rhgundel isplateletactivatingfactorpafanimportantmediatorinbronchialasthma AT hoheuer isplateletactivatingfactorpafanimportantmediatorinbronchialasthma AT lgletts isplateletactivatingfactorpafanimportantmediatorinbronchialasthma |